Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease  by Kistler, Andreas D. et al.
Identification of a unique urinary biomarker profile in
patients with autosomal dominant polycystic kidney
disease
Andreas D. Kistler1, Harald Mischak2, Diane Poster1, Mohammed Dakna2, Rudolf P. Wu¨thrich1 and
Andreas L. Serra1
1Department of Nephrology, University Hospital, Zu¨rich, Switzerland and 2Mosaiques Diagnostics and Therapeutics AG, Hannover,
Germany
To gain some insight into early disease progression in human
autosomal dominant polycystic kidney disease (ADPKD),
we analyzed the urine proteome of 41 young patients with
ADPKD whose renal function was relatively preserved. Using
capillary electrophoresis and mass spectrometry, we
compared these results to those from age-matched healthy
controls and patients with other renal diseases. There were
197 proteins with significantly altered urinary excretion;
and 38 of them could be sequenced, most of which were
collagen fragments. This suggests that there is high turnover
of extracellular matrix proteins. Uromodulin peptides,
previously implicated in tubular injury, were also found
in the urine specimens. These marker proteins were found
to distinguish patients from controls with a high degree
of accuracy. The sensitivity and specificity of this marker
set remained high in an independent validation cohort of
24 patients with ADPKD and 35 healthy controls, and even
in comparisons of patients with a variety of other renal
diseases or patients with kidney or bladder cancer. These
findings present a potential hypothesis for the mechanisms
of disease progression in ADPKD which will need to be
confirmed by further studies.
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Autosomal-dominant polycystic kidney disease (ADPKD) is
the most frequent hereditary kidney disease with a prevalence
between 1:400 and 1:1000,1,2 and accounts for 7–10% of all
patients requiring renal replacement therapy.3 The contin-
uous development and growth of innumerable cysts in both
kidneys starts early in childhood, but most patients remain
asymptomatic until their third or fourth decade of life. After
the occurrence of the symptoms, such as flank pain and
hematuria, the glomerular filtration rate usually starts to
decline at a rapid rate leading to end-stage renal disease
within a decade.4 The disease is caused by mutations in the
PKD1 (85% of cases) or PKD2 gene (15% of cases). Although
these genes were characterized more than a decade ago,5–7 the
precise processes leading to cyst formation and loss of renal
function remain incompletely understood. Several mechan-
isms contributing to cyst formation have been identified,
including a disbalance in epithelial cell proliferation and
apoptosis, secretory defects, altered cell–matrix interactions,
cell polarity, ciliary dysfunction, and altered intracellular
signaling (reviewed by Wilson3).
In human ADPKD with preserved kidney function, renal
tissue is rarely available because kidney biopsy is contraindi-
cated. Consequently, our knowledge of molecular mechan-
isms in the early course of ADPKD is scarce and mainly based
on studies of rodent models for polycystic kidney disease.
Although these animal models are of great value, none of
them fully displays all the features of human ADPKD. The
application of proteomic tools to screen for differentially
excreted proteins in the urine represents a noninvasive
approach to gain insight into pathophysiological processes
and is recently becoming more important.8 Analysis of
body fluids with capillary electrophoresis coupled online to
mass spectrometry (CE-MS) allows the simultaneous detec-
tion of more than 1000 different proteins and peptides
in a sample within a short examination time.9,10 These
proteins and peptides are characterized by their CE migration
time and the mass, while the signal intensity gives a measure
for their relative abundance.11 CE-MS of human urine has
been used to establish the diagnosis or to predict prognosis of
IgA nephropathy,12 diabetic nephropathy,13 ureteropelvic
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2009 International Society of Nephrology
Received 23 October 2008; revised 8 January 2009; accepted 17
February 2009; published online 1 April 2009
Correspondence: Andreas D. Kistler, Department of Nephrology, University
Hospital, Ra¨mistrasse 100, Zu¨rich 8091, Switzerland.
E-mail: andreas.kistler@usz.ch
Kidney International (2009) 76, 89–96 89
junction obstruction,14 and prostate and urothelial
cancer.15,16
The purpose of this investigation was to identify specific
urinary protein biomarkers that enable to distinguish
ADPKD patients from healthy controls and from patients
with other renal diseases. Sequencing of identified biomar-
kers was carried out to gain insight into ADPKD-specific
molecular mechanisms of disease progression.
RESULTS
Clinical characteristics of all ADPKD patients are summar-
ized in Table 1, and demographic data of the control patients
in Table 2. The compiled data of the CE-MS analysis of
urinary samples from 17 ADPKD and its comparison with 86
samples from age- and sex-matched apparently healthy
controls are graphically depicted in Figure 1a and b. To
avoid artifacts based on sporadic signals because of
differences in food, lifestyle, medication, or bacterial
contamination, only peptides that were observed in 450%
of either controls or ADPKD patients were examined, all
others were excluded. The analysis of this data set for
significant differences of single biomarkers (adjusted P-value
o0,05) resulted in the identification of 197 potential urinary
biomarkers, which are listed in Supplementary Table S1. As
the number of potential biomarkers by far exceeded the
number of samples studied, we defined the most consistent
biomarkers by an iterative algorithm leaving out 30% of cases
and controls from the analysis at random. This procedure
was repeated 10 times, and only biomarkers that were found
to be significant in at least 7 of 10 repeats were accepted,
resulting in a reduction to 38 biomarkers, which are listed in
Table 3. The distribution of the urinary biomarkers that
enabled the discrimination between ADPKD and the control
groups is shown in Figure 1c and d.
A support vector machine (SVM)-based model was
created by combining these 38 biomarkers and including
additional controls to enable high specificity. This model
applied to the 17 cases and 86 controls in the training set
discriminated ADPKD from controls with 100% sensitivity
and 98.8% specificity. Upon complete take-one-out cross-
validation, sensitivity was 94.1% and specificity was 98.8%
(area under the receiver operating characteristic curve
(AUC): 0.998).
The support vector machine-based biomarker model
established in the training set was subsequently validated in
an independent masked data set of 24 ADPKD patients and
35 healthy controls. To avoid the introduction of bias because
of differences in the training and the validation set, these two
groups were selected to be similar with respect to clinical and
demographic parameters. The analysis revealed a sensitivity
of 87.5% and a specificity of 97.5% (AUC: 0.95), similar to
the cross-validation of the training set. The ROC curves of
both training and validation sets are shown in Figure 2.
Table 1 | Clinical characteristics of patients with ADPKD
Training set Validation set All
n 17 24 41
Demographic characteristics
Male, n (%) 10 (48.8) 16 (66.7) 26 (63.4)
Female, n (%) 7 (41.2) 8 (33.3) 15 (36.6)
Age, years 31.4±6.8 31.1±5.1 31.2±5.8
SBP (mm Hg) 135.7±17.9 133.9±15.7 134.7±16.5
DBP (mm Hg) 83.2±10.8 86.8±8.5 85.3±9.5
Complications of ADPKD
Arterial hypertension, n (%) 13 (76.5) 18 (75) 31 (75.6)
Antihypertensive treatment, n (%) 7 (41.2) 10 (41.7) 17 (41.5)
ACEi and/or ARB therapy, n (%) 7 (41.2) 10 (41.7) 17 (41.5)
Recurrent flank pain, n (%) 9 (53) 7 (29.2) 16 (39.0)
History of macrohematuria, n (%) 1 (5.9) 4 (16.7) 5 (12.2)
History of UTI, n (%) 2 (11.8) 1 (4.2) 3 (7.3)
History of ICB, n (%) 0 0 0
Renal parameters
Serum creatinine (mmol/l) 85.8±16.6 88.0±14.2 87.1±15.1
Creatinine clearance (C–G; ml/min) 117.7±21.3 111.9±20.3 114.3±20.6
Urinary protein/creatinine (g/mmol) 0.010±0.005 0.008±0.004 0.009±0.004
Total kidney volume (cm3) 1038±673 1063±640 1053±645
ACEi, angiotensin-converting enzyme inhibitor; ADPKD, autosomal-dominant polycystic kidney disease; ARB, angiotensin receptor blocker; C–G, estimated according to
Cockcroft–Gault; DBP, diastolic blood pressure; ICB, intracranial bleeding; SBP, systolic blood pressure; UTI, urinary tract infection.
Data are mean±s.d. if not otherwise depicted.
Table 2 | Demographic characteristics of control patients
N
Age, years
(mean±s.d.)
Gender
(% female)
Normal controls
Training set 86 30±10 52
Validation set 35 30±5 60
Additional controls 189 37±15 49
Elderly patients 127 68±10 55
Chronic kidney diseases 150 45±19 26
Renal cell carcinoma 113 69±10 53
Bladder carcinoma 112 64±12 23
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To further evaluate the specificity of the ADPKD urinary
proteomic pattern, the model was additionally tested in
normal controls (16 of 189 positive, 91.5% specificity, AUC:
0.923), patients with different chronic renal diseases (7 of 150
positive, 95.3% specificity, AUC: 0.955), with bladder cancer
(17 of 112 positive, 84.4% specificity, AUC: 0.919), with renal
cell cancer (21 of 113 positive, 81.4% specificity, AUC: 0.895),
and healthy individuals aged 460 years (40 of 127 positive,
68.5% specificity, AUC: 0.838). When evaluating all data sets
combined (24 cases from the validation cohort and 691
controls), the AUC was 0.910. These results reveal a high
specificity, which is reduced in individuals of advanced age. It
can be noted that both groups of patients with renal cell
cancer and bladder cancer, in which the specificity of the
model was slightly reduced, were aged 460 years.
To test, whether disease severity or antihypertensive
treatment influences the accuracy of the biomarker model,
all ADPKD patients from the training and the validation sets
were combined. Their score in the 38 biomarker model did
not correlate with total kidney volume, age-adjusted total
kidney volume, proteinuria, or medication with either
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers (data not shown). Thus, the biomarkers
that have been included in the model are relatively robust and
not affected by these covariates.
We were able to obtain sequences from 38 of the 197
potential biomarkers, as shown in Table 3. The 38 sequenced
peptides represented 13 fragments of collagen a1(I) (6
upregulated and 7 downregulated), one fragment of collagen
a2(I) (upregulated), 11 fragments of collagen a1(III) (8
upregulated and 3 downregulated), one fragment of collagen
a1(XVIII) (upregulated), 6 fragments of uromodulin (2
upregulated and 4 downregulated), 2 fragments of a1-
antitrypsin (both upregulated), and one fragment of each
cystatin B (upregulated), polymeric immunoglobulin recep-
tor (upregulated), Naþ /Kþ–ATPase g-chain (upregulated),
and ProSAAS (downregulated).
Of all sequenced biomarkers, 6 were present among the 38
biomarkers that were used for classification. We subsequently
examined an ADPKD-specific biomarker model based on
only these six sequenced peptides. Their combination
enabled classification of the training set with a sensitivity of
100% and a specificity of 95.5%. Upon complete cross-
validation, a sensitivity of 94.1% and a specificity of 94.2%
(AUC: 0.97) could be obtained. This biomarker model was
again tested using the same independent masked validation
set as above. Here, a sensitivity of 91.7% and a specificity of
80.0% could be obtained (AUC: 0.89). These results indicate
a high diagnostic value of these six urinary biomarkers.
However, the additional, yet-unidentified 32 biomarkers
enhance the performance of the classification.
DISCUSSION
We have identified and validated a distinct pattern of
polypeptides excreted in the urine that characterizes patients
with ADPKD. This is the first study that shows a unique
urine proteome profile, which distinguishes ADPKD patients
from healthy controls and from patients with various other
forms of renal diseases or pathologies of the excretory urinary
tract.
In several recently published reports on biomarkers for
different renal diseases, the potential biomarkers were mostly
defined on small cohorts of patients, and no statistical
correction for multiple testing was used (see Candiano
et al.,17 Zhou et al.,18 Varghese et al.,19 and Weissinger
et al.20). As a consequence, most of the initially identified
potential biomarkers failed in an independent validation set,
if validation was even performed. These shortcomings have
resulted in the proposition for guidelines for clinical
proteomics.21 Therefore, and in accordance with these
guidelines, we have used a large number of data sets,
statistics adjusted for multiple testing, and a masked
independent validation set to define urinary biomarkers for
ADPKD.
A biomarker model was developed that distinguishes
ADPKD patients from age-matched healthy controls with a
high degree of reliability. Validation in an independent
cohort confirmed the high sensitivity and high specificity of
the model. We have included only relatively young ADPKD
patients with well-preserved renal function. Furthermore, the
urinary proteomic model was capable to distinguish between
ADPKD and a large number of different renal diseases with a
high degree of specificity. Therefore, the identified urinary
markers likely reflect ADPKD-specific pathophysiological
ControlADPKD
Figure 1 | Urine proteomic pattern in ADPKD patients and
healthy individuals. (a) Compiled (average) protein patterns of
all urine samples from patients with ADPKD (n¼ 17; left panel)
and the control group in the training set (n¼ 86; right panel). The
molecular mass (0.8–15 kDa, on a logarithmic scale) is plotted
against normalized migration time (18–45 min). Signal intensity is
encoded by peak height and color. (b) Distribution of the 38
potential diagnostic biomarkers for ADPKD. All statistically
significant biomarkers from Table 3 are shown.
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processes associated with cyst formation and expansion,
rather than just an impaired renal function. The score derived
from the 38 biomarker model did not correlate with clinical
markers of disease severity or treatment with angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers, indicating that the performance of the model is not
affected by these covariates.
Although the diagnosis of ADPKD is in most cases easily
established based on an age-dependent cystic renal pheno-
type and a positive family history,22 current markers
predicting disease progression are less reliable. There is
considerable inter- and intrafamilial variability in the rate of
progression to kidney failure, and renal prognosis often
cannot be determined by the individual’s phenotype during
early stages of the disease.23 In light of recently emerging
therapeutic options for ADPKD, it will be of paramount
importance to select patients with rapidly progressive disease
for treatment and avoid exposing patients with mild disease
Table 3 | Potential biomarkers used in the SVM-based model
Peptide ADPKD Control P-value
ROC
ID Mass CE time Frequency Amplitude Frequency Amplitude Unadjusted BH AUC Sequence Protein
4976 902.41 20.85 1 2.97 (3.02) 0.82 2.08 (2.59) 4.20E10 2.23E08 0.8570451
11705 984.46 24.92 0.76 1.66 (2.17) 0.22 0.40 (1.85) 5.30E05 8.67E04 0.8269494
13188 1013.37 25.17 1 3.09 (3.16) 0.93 2.66 (2.88) 3.27E04 3.56E03 0.7250342
16320 1075.49 20.61 0.88 2.20 (2.47) 0.22 0.43 (1.93) 2.52E06 6.31E05 0.9015048
16875 1082.52 21.69 0.76 1.57 (1.94) 0.34 0.65 (1.86) 1.66E03 1.25E02 0.7346101
18939 1114.48 24.21 0.82 1.83 (2.14) 0.39 0.87 (2.24) 5.06E03 2.77E02 0.6928865
19773 1128.39 33.59 1 3.12 (3.06) 0.92 2.77 (3.01) 3.44E03 2.03E02 0.6155951
23224 1178.39 20.71 0.59 1.40 (2.38) 0.21 0.48 (2.26) 6.77E03 3.41E02 0.7024624
23360 1179.52 27.11 1 3.09 (3.11) 0.86 2.39 (2.81) 1.07E08 4.56E07 0.8720930
23697 1186.53 22.39 0.94 2.76 (2.88) 0.89 2.54 (2.88) 6.23E03 3.17E02 0.7455540 DDGEAG
KpGRpG
Collagen alpha-1
(I) chain [231–242]
24502 1200.54 25.03 0.53 1.70 (3.86) 0.15 0.40 (2.07) 1.01E02 4.63E02 0.6949384
28103 1257.44 33.92 1 3.40 (3.39) 0.97 3.09 (3.25) 2.19E03 1.52E02 0.6839945
32471 1326.56 27.11 0.12 0.36 (3.05) 0.64 1.81 (2.77) 2.32E05 4.30E04 0.7335841
34017 1354.64 22.14 0.71 1.60 (2.24) 0.14 0.25 (1.78) 8.28E05 1.19E03 0.8283174
35535 1383.59 27.63 1 2.60 (2.65) 0.63 1.53 (2.37) 7.82E12 5.11E10 0.8112175 GSpGGpGS
DGKpGPpG
Collagen alpha-1
(III) chain [540–555]
48176 1580.88 23.87 0.41 1.14 (2.81) 0.85 2.64 (3.14) 7.06E04 6.39E03 0.7735978 IDQSRVL
NLGPITR
Uromodulin [593–606]
48580 1588.71 30.15 1 2.88 (2.90) 0.51 1.07 (2.12) 1.61E06 4.55E05 0.9227086 TGLSMDGG
GSPKGDVDP
Na/K-ATPase gamma
chain [2–18]
52189 1640.58 23.24 1 3.69 (3.67) 0.92 3.31 (3.65) 2.00E03 1.44E02 0.6067031
54525 1680.75 30.03 0.94 3.22 (3.41) 0.7 2.43 (3.50) 4.40E03 2.46E02 0.5153899 GLpGTGGP
pGENGK
pGEp
Collagen alpha-1
(III) chain [642–659]
54688 1684.67 30.66 0.88 2.92 (3.37) 0.25 0.83 (3.30) 1.66E07 5.87E06 0.8324213
54687 1684.67 31.75 0.24 0.62 (2.58) 0.74 2.28 (3.17) 5.81E05 9.32E04 0.7602599
54703 1684.71 29.65 0.12 0.26 (2.20) 0.57 1.43 (2.50) 2.69E05 4.67E04 0.7356361
56493 1716.66 20.18 0.71 1.81 (2.60) 0.54 1.36 (2.46) 5.41E03 2.90E02 0.7127223
73434 2067.82 20.62 1 3.04 (3.12) 0.89 2.73 (3.16) 5.83E03 3.02E02 0.5916553
111001 2825.27 24.49 1 4.18 (4.21) 0.98 4.12 (4.22) 2.20E03 1.52E02 0.5745554 ERGEAGIpG
VpGAKGE
DGKDGSpG
EpGANG
Collagen alpha-1
(III) chain [448–477]
124193 3166.27 22.06 0.71 1.96 (2.85) 0.29 0.64 (2.13) 8.73E04 7.42E03 0.7831737
125103 3202.43 30.6 0.47 1.09 (2.41) 0.07 0.14 (2.00) 9.06E03 4.28E02 0.6792066
139455 3630.44 21.78 0.71 1.83 (2.57) 0.24 0.53 (2.32) 6.10E04 6.03E03 0.7821477
143344 3774.81 28.23 0.24 0.64 (2.77) 0.51 1.38 (2.75) 7.26E03 3.61E02 0.7551300
148086 3986.65 20.6 1 3.69 (3.72) 0.71 2.25 (3.24) 9.68E13 7.48E11 0.8734610
149624 4043.64 20.39 0.94 2.83 (3.10) 0.44 1.20 (2.70) 6.60E07 1.93E05 0.8098495
153832 4196.75 20.84 0.71 1.89 (2.78) 0.32 0.72 (2.28) 2.17E03 1.52E02 0.7619699
159396 4409.89 20 0.82 2.56 (3.19) 0.38 1.02 (2.73) 2.16E04 2.58E03 0.7835157
165781 4671.82 23.28 0.82 2.12 (2.65) 0.66 1.57 (2.45) 1.15E02 4.95E02 0.6853625
167786 4771.07 20.2 0.76 2.38 (3.08) 0.3 0.76 (2.51) 2.71E04 3.11E03 0.8043776
168314 4799.96 23.81 1 3.48 (3.53) 0.87 2.85 (3.24) 1.39E05 2.81E04 0.7387141
177664 6169.57 24.77 0.76 2.46 (3.11) 0.18 0.47 (2.67) 2.38E05 4.31E04 0.8467852
184058 8837.41 21.06 1 3.48 (3.68) 0.41 1.18 (2.86) 1.28E21 5.46E19 0.9350205
ADPKD, autosomal-dominant polycystic kidney disease; AUC, area under the curve; BH, adjusted according to Benjamini and Hochberg; CE, capillary electrophoresis; ROC,
receiver operating characteristic; SVM, support vector machine.
Given are the internal ID, mass, capillary electrophoresis migration time, frequency (i.e., the proportion of patients in whose urine the denoted peptide was detectable), and
mean (s.d.) amplitude (i.e., the peak intensity of the denoted peptide in the mass spectrum) in ADPKD patients and controls, P-value for the comparison of cases and
controls (unadjusted and adjusted according to the Benjamini and Hochberg49), ROC value in the training set, and, if applicable, sequence, parental protein, and position of
the peptide within the parental protein sequence.
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to expensive therapies with potential side effects. Our finding
of an ADPKD-specific urinary proteomic pattern suggests
that the progression rate of the disease might also be reflected
by the urinary proteome. The scores of the reported
biomarker model did not correlate with age-adjusted total
kidney volume, because these biomarkers have been selected
for their high consistency among different ADPKD patients
and therefore unlikely reflect disease severity. To define a
prognostic model, the complete proteomic patterns derived
by CE-MS will have to be correlated with longitudinal data
on kidney volume growth in ADPKD patients. However, as
proteomic differences among patients with ADPKD are likely
to be smaller than those between ADPKD and control
patients, a larger sample size will be required to define
reliable progression markers.
The data presented here and elsewhere (Rossing et al.,13
Decramer et al.,14 and Julian et al.24) indicate that a
combination of several markers to a model results in a much
higher test accuracy than the use of single biomarkers. The
capability to simultaneously detect a large number of small
proteins and peptides represents a major advantage of CE-
MS. It is virtually impossible to quantify all the 38 peptides of
our model appropriately by alternative means. As pointed
out recently,25,26 it is unlikely that the biomarkers can be
accurately displayed by an immunological assay, as such
assays generally do not enable assessment of post-transla-
tional modifications (including processing of C and N
termini). Alternative techniques to display the identified
biomarkers would include multiple reaction monitoring or
immunocapture, followed by matrix-assisted laser deso-
rption/ionization-time of flight mass spectrometry. However,
the establishment of such assays is still a considerable
challenge, and may not be successful. Furthermore, both
approaches would in addition require the assessment of
internal calibrants.26 Therefore, and as CE-MS is a rapid and
robust method, we propose the clinical use of CE-MS (in case
the above-mentioned prognostic biomarkers can be defined)
rather than the development of an alternative test for the
detection of the described fragments.
We were able to determine the amino acid sequence of 38
of the total 197 differentially excreted polypeptides. As
outlined in detail in several recent reports, although
sequencing of tryptic digests can be considered routine,
sequencing of naturally occurring peptides still represents a
challenge that often cannot be met, to a large degree, likely
because of post-translational modifications.27,28 Most of the
identified peptides represent collagen type I or type III
fragments. The expansion of cysts in ADPKD requires
adaptive changes of the extracellular matrix (ECM), and
several studies on polycystic kidney disease have revealed
ECM abnormalities.29,30 Serum levels of matrix metallopro-
teinases have been found to be increased in ADPKD
patients,31 and the matrix metalloproteinase inhibitor,
batimastat, reduced cyst growth in (cy/þ ) rats, a rodent
model of polycystic kidney disease.32 We could recently show
that sirolimus, which was effective to slow cyst growth and
preserve renal function in (cy/þ ) rats, did also ameliorate
the enhanced expression of matrix metalloproteinases in
these animals.33 Our finding that many collagen fragments
are differentially excreted in ADPKD underscores the
importance of ECM remodeling during disease progression.
Not only upregulation but also downregulation of certain
collagen fragments is observed in ADPKD. However, the
majority of collagen fragments are upregulated, indicating
increased protease activity. It is tempting to speculate that
disease-specific changes in protease activity are responsible
for this observation.
It is interesting that, the proteomic pattern of young
ADPKD patients overlapped with that of apparently healthy
elderly patients. The aging of the kidney is associated with an
extensive remodeling of the ECM as reflected by the increased
expression of ECM components.34–36 Although the signifi-
cance of ECM turnover during aging is not clear, these
processes do likely contribute to interstitial fibrosis in the
aging kidney. Our finding might describe a common pathway
in ADPKD and in aging of the kidney.
Several uromodulin fragments were also differentially
excreted in the urine of ADPKD patients. Uromodulin, which
is identical to Tamm–Horsfall protein, is the most abundant
protein in the urine of healthy individuals. Urinary secretion
occurs by proteolytic cleavage of the large N-terminal
ectodomain from the glycosylphosphatidylinositol-anchored
counterpart exposed at the luminal cell surface of the thick
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Figure 2 | Performance of the biomarker models using ROC
analysis (with 95% CI). (a) Classification results in the cross-
validations based on 38 biomarkers specific for ADPKD in the
training set consisting of 17 cases and 86 controls. (b)
Classification results based on the same 38 biomarkers in the
validation set consisting of 59 blinded samples (24 cases and 35
controls). (c) Classification results in the cross-validations based on
the six sequenced biomarkers specific for ADPKD in the training
set. (d) Classification results based on the same six biomarkers in
the validation set.
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ascending limb of Henle’s loop.37 Although the physiological
role of uromodulin is uncertain, it is believed to be involved
in the pathogenesis of various renal tubular disorders, such as
cast nephropathy, urolithiasis, and tubulointerstitial nephritis
(reviewed by Serafini-Cessi et al.38). Moreover, reduced
urinary Tamm–Horsfall protein excretion is considered a
reliable index of distal tubular cell damage.39–41 A recent
study showed that familial juvenile hyperuricemic nephro-
pathy and autosomal-dominant medullary cystic kidney
disease 2 arise from mutations in the uromodulin gene.42
There has been no report on altered expression, processing,
or urinary excretion of uromodulin in ADPKD so far. In can
be noted that, all fragments differentially excreted in ADPKD
are located in the C-terminal of the putative cleavage site,
thus representing further proteolytic processing of the
glycosylphosphatidylinositol-anchored residual protein moi-
ety after proteolytic release of the N-terminal ectodomain.
The amount of intact N-terminal ectodomain excreted in the
urine of ADPKD patients cannot be estimated on the basis of
our data because of its large size and the limitation of CE-MS
to small-molecular-weight proteins.
Taken together, we were able to identify a urinary
proteomic ‘footprint’ of ADPKD, which distinguishes the
disease from health and from other renal diseases with a high
degree of reliability. The ADPKD-specific urinary proteomic
pattern most likely mirrors alterations in the ECM, which
occur early in the course of the disease when the excretory
renal function is still preserved. Further studies are needed to
elucidate the pathophysiological significance of the altera-
tions in the excretion of collagen and uromodulin fragments
and to establish prognostic biomarkers for ADPKD.
MATERIALS AND METHODS
Patients and procedures
The ADPKD subjects for this study were participants of an earlier
described registry.43 Patients affected by ADPKD, aged between 19
and 41 years with preserved renal function (estimated creatinine
clearance X70 ml/min according to the Cockcroft–Gault formula)
were included. The diagnosis of ADPKD was based on a positive
family history and ultrasonographic diagnostic criteria.22 A detailed
medical history was obtained, including ADPKD-related symptoms,
previous hospitalization, and medication. Urine samples were
collected in the morning, after voiding the first urine of the day.
Blood pressure measurements and blood analyses were performed as
described earlier.43 In addition, all ADPKD patients underwent renal
magnetic resonance imaging without contrast media. Kidney
volumes were determined from magnetic resonance imaging
sequences with high accuracy and reliability as reported earlier.43
Urine samples of 17 ADPKD patients and 86 age- and sex-
matched apparently healthy individuals (mean±s.d. age 30.4±4.9
years; range 18–40; 47.7% males) were analyzed to identify an
ADPKD-specific proteomic pattern. The identified pattern was
validated by analyzing urine samples from another 24 ADPKD
patients and 35 healthy controls (mean±s.d. age 30.5±9.6 years;
range 18–40; 31.4% males).
Additional urine samples from healthy controls (n¼ 189), elderly
healthy controls (n¼ 127), patients with chronic kidney disease
(n¼ 150; 42 IgA nephropathy; 32 membranous glomerulonephritis;
30 diabetic nephropathy; 27 focal segmental glomerulosclerosis; and
17 ANCA vasculitis) and from patients with bladder (n¼ 112) or
renal cell cancer (n¼ 113) were collected as described ear-
lier.13,16,24,44 Shortly, second or third urine (mid-stream) of the
morning was collected and frozen within 1 h below 201C, as
suggested in recently published recommendations.45 Also, following
these recommendations, no protease inhibitors were added. The
clinical data on the additional controls were described in several
recent manuscripts.12,16,20,24 Their demographic data are summar-
ized in Table 2.
Informed consent was obtained from all patients and healthy
controls after local ethics committee approval. These studies were
performed in accordance with the Declaration of Helsinki
Principles.
Sample preparation and CE-MS analysis
All urine samples for CE-MS analyses were stored at 201C until
analysis and underwent a maximum of two freeze/thaw cycles. We
found no significant differences when samples went through up to
three freeze/thaw cycles (Mischak, unpublished observation). A 0.7-ml
aliquot was thawed immediately before use and diluted with 0.7 ml of
2 M urea, 10 mM NH4OH containing 0.02% sodium dodecyl sulfate. To
remove higher molecular mass proteins, the sample was filtered using
Centrisart ultracentrifugation filter devices (20 kDa molecular weight
cut-off (MWCO); Sartorius, Goettingen, Germany) at 3000 g until
1.1 ml of filtrate was obtained. This filtrate was then applied onto a
PD-10 desalting column (Amersham Bioscience, Uppsala, Sweden)
equilibrated in 0.01% NH4OH in high-performance liquid chromato-
graphy-grade H2O (Roth, Karlsruhe, Germany) to decrease matrix
effects by removing urea, electrolytes, salts, and to enrich polypeptides.
Finally, all samples were lyophilized, stored at 4 1C, and suspended in
high-performance liquid chromatography-grade H2O shortly before
CE-MS analysis, as described.16
CE-MS analysis was performed as described16,46 using a P/
angiotensin-converting enzyme MDQ Capillary Electrophoresis Sys-
tem (Beckman Coulter, Fullerton, CA, USA) on-line coupled to a
Micro-TOF MS (Bruker Daltonic, Bremen, Germany). The ESI sprayer
(Agilent Technologies, Palo Alto, CA, USA) was grounded, and the
ion-spray interface potential was set between 4 and 4.5 kV. Data
acquisition and MS acquisition methods were automatically controlled
by the CE through contact-close-relays. Spectra were accumulated
every 3 s, over a range of m/z 350–3000. Accuracy, precision, selectivity,
sensitivity, reproducibility, and stability of the analytical platform were
indicated and described in great detail elsewhere.16
Data processing and cluster analysis
Mass spectral ion peaks representing identical molecules at different
charge states were deconvoluted into single masses using the
MosaiquesVisu software.47 Migration time and ion signal intensity
(amplitude) were normalized using internal polypeptide stan-
dards,15 which seem to be unaffected by any disease state studied
to date.27 The resulting peak list characterizes each polypeptide by
its molecular mass (kDa), normalized migration time (min), and
normalized signal intensity. All detected polypeptides were depos-
ited, matched, and annotated in a Microsoft SQL database, allowing
comparison of multiple samples (patient groups). To determine
whether polypeptides observed in different samples were identical, a
linear function was used that provided an allowed 50 p.p.m. absolute
mass deviation for peptides of 800 Da, which increased linearly to
100 p.p.m. for peptides with a maximum mass of 20 kDa. A similar
linear function was used when comparing CE migration times, with
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small peptides being allowed a 2% and higher mass peptides a 5%
absolute time deviation to account for the decreased resolution of
large species. CE-MS data of all individual samples can be accessed
in Supplementary Table 2.
Disease-specific polypeptide patterns were generated using
support vector machine-based MosaCluster software.14
Statistical methods, definition of biomarkers, and sample
classification
Sensitivity and specificity were calculated on the basis of tabulating
the number of correctly classified samples. Confidence intervals
(95% CI) based on exact binomial calculations were carried out in
MedCalc (version 8.1.1.0, MedCalc Software, Mariakerke, Belgium;
http://www.medcalc.be). The receiver operating characteristic
(ROC) plot was obtained by plotting all sensitivity values on the y
axis against their equivalent 1-specificity values on the x axis for all
available thresholds (MedCalc Software). The AUC was evaluated, as
it provides a single measure of overall accuracy that is not dependent
on a particular threshold.48 The reported unadjusted P-values were
calculated using the natural logarithm-transformed intensities
and the Gaussian approximation to the t-distribution. Statistical
adjustment for multiple testing was carried out by the method
described by Benjamini and Hochberg.49
Sequencing of polypeptides
Candidate biomarkers were sequenced using liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS) analysis as
recently described in detail.50. Further analysis was performed using
instruments with electron transfer dissociation (ETD) capabil-
ity.51–53 Immediately before the analysis, samples were re-suspended
(50ml in 100 mM acetic acid), bomb-loaded onto a 360 75mm
microcapillary pre-column, and connected to a 360 50mm
analytical column with an B1 mm tip pulled with a laser puller
(both columns were packed in-house with approximately 5–8 cm of
C18 resin). Peptides were separated by nanoflow reversed-phase
high-performance liquid chromatography (Agilent 1100; flow split
by tee to B60nl/min) and introduced into either an ETD-enabled
Thermo Fisher linear trap quadrupole (LTQ) ion trap (Thermo
Fisher Scientific, San Jose, CA, USA) or Thermo Fisher LTQ-
Orbitrap (Thermo Fisher Scientific, Bremen, Germany) mass
spectrometer, also capable of ETD analysis, through nanoelectros-
pray ionization (nano-ESI). Samples were analyzed using the LTQ in
a data-dependent manner, with the five most abundant species
subjected to both ETD and collision-activated dissociation (CAD)
fragmentation (in separate alternating scans). Ion trap instrumental
parameters most conducive to achieving the highest fragmentation
efficiencies for both CAD and ETD were used as described
recently.54 Spectral data was converted into .dta files (DTA’s) and
searched against the IPI human non-redundant database using the
Open Mass Spectrometry Search Algorithm (OMSSA; free from
NCBI, http://pubchem.ncbi.nlm.nih.gov/omssa/); e-value cutoff was
0.01. All matched sequences were manually validated.
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